Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
Yong-Wei Xu, Yan Song, Jun Tian, Ba-Cui Zhang, Yu-Sheng Yang, Jing Wang
BACKGROUND: Gastric cancer (GC) is a significant health problem worldwide, and early detection and accurate diagnosis are crucial for improving patient outcomes. Crawling-type gastric adenocarcinoma is a rare subtype of GC that has unique histopathological and clinical characteristics, and its diagnosis and management can be challenging. This pathological type of GC is also rare. CASE SUMMARY: Here, we report the case of a patient who underwent ordinary endoscopy, narrow-band imaging, and endoscopic ultrasonography intending to determine the extent of tumor invasion and upper abdominal enhanced computed tomography and whether there was tumor metastasis...
April 15, 2024: World Journal of Gastrointestinal Oncology
#22
REVIEW
Sara Ramos Lopes, Claudio Martins, Inês Costa Santos, Madalena Teixeira, Élia Gamito, Ana Luisa Alves
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, being the third most commonly diagnosed malignancy and the second leading cause of cancer-related deaths globally. Despite the progress in screening, early diagnosis, and treatment, approximately 20%-25% of CRC patients still present with metastatic disease at the time of their initial diagnosis. Furthermore, the burden of disease is still expected to increase, especially in individuals younger than 50 years old, among whom early-onset CRC incidence has been increasing...
April 15, 2024: World Journal of Gastrointestinal Oncology
#23
JOURNAL ARTICLE
Kai-Lin Jiang, Xiang-Xiang Wang, Xue-Jiao Liu, Li-Kun Guo, Yong-Qi Chen, Qing-Ling Jia, Ke-Ming Yang, Jiang-Hong Ling
BACKGROUND: Human-derived gastric cancer organoids (GCOs) are widely used in gastric cancer research; however, the culture success rate is generally low. AIM: To explore the potential influencing factors, and the literature on successful culture rates of GCOs was reviewed using meta-analysis. METHODS: PubMed, Web of Science, and EMBASE were searched for studies. Two trained researchers selected the studies and extracted data. STATA 17.0 software was used for meta-analysis of the incidence of each outcome event...
April 15, 2024: World Journal of Gastrointestinal Oncology
#24
EDITORIAL
Antonio Pesce, Nicolò Fabbri, Diletta Iovino, Carlo Vittorio Feo
In this editorial, we have analyzed the historical evolution of rectal and breast cancer surgery, focusing on the progressive reduction of demolitive approaches and the increasing use of more conservative strategies, accompanied by a growing emphasis on perioperative treatments aimed at enhancing surgical outcomes. All of these changes have been made possible due to an increased awareness and understanding of oncological diseases and improved perioperative treatments.
April 15, 2024: World Journal of Gastrointestinal Oncology
#25
JOURNAL ARTICLE
Xiao-Min Zhang, Ting Yang, Ying-Ying Xu, Bao-Zhong Li, Wei Shen, Wen-Qing Hu, Cai-Wen Yan, Liang Zong
BACKGROUND: The combination of programmed cell death protein-1 (PD-1) inhibitor and chemotherapy is approved as a standard first- or second-line treatment in patients with advanced oesophageal or gastric cancer. However, it is unclear whether this combination is superior to chemotherapy alone. AIM: To assess the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction (GEJ) cancer, or oesophageal carcinoma...
April 15, 2024: World Journal of Gastrointestinal Oncology
#26
JOURNAL ARTICLE
Eziafa I Oduah, Susan T Sharfstein, Nagashree Seetharamu, Steven R Grossman, Larisa Litovchick
Lung cancer is the leading cause of cancer mortality. Despite therapeutic advances in recent years, new treatment strategies are needed to improve outcomes of lung cancer patients. Mutant p53 is prevalent in lung cancers and drives several hallmarks of cancer through a gain-of-function oncogenic program, and often predicts a poorer prognosis. The oncogenicity of mutant p53 is related to its stability and accumulation in cells by evading degradation by the proteasome. Therefore, destabilization of mutant p53 has been sought as a therapeutic strategy, but so far without clinical success...
2024: Frontiers in Oncology
#27
JOURNAL ARTICLE
Thomas Jordan, Thitikorn Nuamek, Isabella Fornacon-Wood, Raffaele Califano, Joanna Coote, Margaret Harris, Hitesh Mistry, Paul Taylor, David Woolf, Corinne Faivre-Finn
INTRODUCTION: The use of patient-reported outcomes (PROs) has been shown to enhance the accuracy of symptom collection and improve overall survival and quality of life. This is the first study comparing concordance and patient preference for two PRO tools: Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE® ) and the adapted-REQUITE Lung Questionnaire. MATERIALS AND METHODS: Patients with lung cancer were recruited to the study while attending outpatient clinics at a tertiary cancer centre...
2024: Frontiers in Oncology
#28
JOURNAL ARTICLE
Josh Elbaz, Alyson Haslam, Vinay Prasad
BACKGROUND: The US Food and Drug Administration (FDA) has expanded the use of surrogate markers in drugs approved for oncology/hematology indications. This has likely resulted in a greater number of approvals and possibly drugs coming to market faster, but it is unknown whether these drugs also improve overall survival (OS) for patients taking them. METHODS: We sought to estimate the percentage of oncology drugs that have shown to improve OS in a cross-sectional analysis of US FDA oncology drug approvals (2006-2023)...
April 2024: Cancer Medicine
#29
JOURNAL ARTICLE
Kenneth P Tercyak, Mary Rose Yockel, Jacqueline Eyl, Chiranjeev Dash, Dorothy Jones-Davis, Marcelo M Sleiman, Liza Manfred, Dia Stone, Karen Howenstein, Denise Flessate Harley, Mingqian Liu, Catherine J Scharon, Annalise Phillips, Rebecca B Riggins
Children's early awareness about cancer, through exposure to cancer biology and prevention strategies and research principles, is a promising focus of education and learning. It may also benefit the pipeline of people entering into science, technology, engineering, and math (STEM) careers. We describe an educational pilot program for elementary school students, using developmentally appropriate activities focused on cancer at a museum dedicated to children's maker-centered learning and STEM. The program was implemented through a public school in Washington, DC serving students underrepresented in STEM...
April 24, 2024: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
#30
REVIEW
Vítor Silva, Cristiano Matos
INTRODUCTION: Treatment of cancer has been improved with the discovery of biological drugs that act as immune checkpoint inhibitors. In 2017, FDA designated pembrolizumab, an immune checkpoint inhibitor employed in immunotherapy, as the first tissue-agnostic cancer treatment. OBJECTIVES: To review pembrolizumab's use in oncology, gather and examine the latest discoveries regarding the effectiveness of pembrolizumab in cancer treatment. METHODOLOGY: A literature review was conducted through PubMed(Medline) from January 2015 to December 2023 using "pembrolizumab", "cancer" and "treatment" as search terms...
April 24, 2024: Clinical & Translational Oncology
#31
JOURNAL ARTICLE
P Baird, K Drinkwater, J Forrest, A J Stewart
AIMS: This audit examined UK vulvar cancer practice from March 2018 to January 2019 and compared it to standards from national and international recommendations. Follow-up data collection in 2020 examined patient outcomes and toxicity. MATERIALS AND METHODS: Audit standards were based on Royal College of Radiologists (RCR) guidance and published literature. A web-based questionnaire was sent to the audit leads at all cancer centres in the UK. Prospective data collection included patient demographics, tumour characteristics, radiotherapy indications, dosimetry, timelines, and follow-up data...
March 29, 2024: Clinical Oncology: a Journal of the Royal College of Radiologists
#32
JOURNAL ARTICLE
Amanda Drury, Vanessa Boland, Maura Dowling
OBJECTIVE: To discuss the opportunities and challenges of implementing patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) within advanced practice nursing services in cancer care. METHODS: This discussion paper has been informed by an environmental scan of evidence from systematic reviews and primary studies evaluating the use and implementation of PROMs and PREMs. Literature from the contexts of cancer and chronic disease, including nursing and multidisciplinary supportive care literature, has been included...
April 23, 2024: Seminars in Oncology Nursing
#33
JOURNAL ARTICLE
Yu Xu, Fan Xiong, Huayi Li, Hong Zheng, Jie Jiang, Qingshui Li, Guiling Li, Weidong Zhao, Rong Li, Jundong Li, Rong Xie, Ruifang An, Huifeng Zhang, Qinglei Gao
BACKGROUND: Platinum-resistant, recurrent ovarian cancer has an abysmal prognosis with limited treatment options. Poly-(ADP-ribose)-polymerase (PARP), angiogenesis, and immune checkpoint inhibitors might improve the outcomes of platinum-resistant, recurrent ovarian cancer, but accurate patient selections for those therapies remain a significant clinical challenge. PRIMARY OBJECTIVE: To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer...
April 23, 2024: International Journal of Gynecological Cancer
#34
REVIEW
Sudha Rajagopal, Xiaomei Yao, Wadid Abadir, Tara D Baetz, Alexandra Easson, Gregory Knight, Elaine McWhirter, Carolyn Nessim, Cheryl F Rosen, Alexander Sun, Frances C Wright, Teresa M Petrella
PURPOSE: Appropriate surveillance of patients with melanoma treated with curative intent is vital to improve patient outcomes. A systematic review was conducted to capture locoregional recurrence and metastatic disease, and to evaluate the effectiveness of various surveillance strategies. METHODS: MEDLINE, EMBASE, PubMed, Cochrane Database of Systematic Reviews, and National Cancer Institute Clinical Trials Database were searched. Randomized controlled trials (RCTs) and comparative studies reporting at least one patient-related outcome were included...
April 10, 2024: Surgical Oncology
#35
JOURNAL ARTICLE
Seijong Kim, Jung Wook Huh, Woo Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Yong Beom Cho, Yoonah Park, Jung Kyong Shin
BACKGROUND: Locally advanced rectal cancer patients often display favorable responses and favorable oncologic outcomes. Due to the low recurrence rate, there is scarcity of studies investigating the prognostic factors influencing their survival. Therefore, our study sought to assess the prognostic factors associated with survival in rectal cancer patients who achieved either a pathologic complete response or a pathologic stage I after neoadjuvant chemoradiotherapy combined with radical resection...
April 20, 2024: European Journal of Surgical Oncology
#36
REVIEW
Titus Hutch Jr Yi Zheng Yim, Kok Yang Tan
Amidst trends of a rapidly ageing population with better surgical outcomes for geriatric patients, it is imperative to consider outcome measures beyond mortality and morbidity rates. In fact, the preservation of one's postoperative function has been cited as a key priority for older adults and is a crucial determinant of postoperative independence and survival. This review aims to examine the prevalence of perioperative function reporting amongst older surgical patients undergoing elective major abdominal surgery for cancer...
April 17, 2024: European Journal of Surgical Oncology
#37
JOURNAL ARTICLE
Suvi T Marjasuo, Tiina E Lehtimäki, Laura E Koskenvuo, Anna H Lepistö
AIM: Mesorectal extranodal tumor deposits (TDs) are identified in many rectal cancers. Their radiological features differ from metastatic lymph nodes, and they can be detected with magnetic resonance imaging (MRI). The purpose of this study was to determine the prevalence of rectal cancer TDs detected with MRI and their impact on overall (OS), cancer-specific (CSS), and disease-free survival (DFS) and the local recurrence rate. METHOD: In this retrospective cohort study, we screened all 525 consecutive rectal cancer patients who underwent surgery during 2017-2018 in a tertiary center...
April 16, 2024: European Journal of Surgical Oncology
#38
JOURNAL ARTICLE
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E Vera Badillo, J Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Grünwald, Michael Hölzel, Markus Eckstein
PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS: We established a NECTIN4 -specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108)...
April 24, 2024: Journal of Clinical Oncology
#39
JOURNAL ARTICLE
S Velázquez-Rodríguez, M A Clara-Altamirano, D Y García-Ortega, A R Lizcano-Suárez, H Martínez-Said, V Villavicencio-Valencia, M Cuellar-Hubbe
INTRODUCTION: reconstruction of large bone defects using modular knee arthroplasty (MKA) presents a significant challenge in terms of functionality. The objective of the present work was to identify the different prognostic factors associated with failure of MKA in cancer patients. MATERIAL AND METHODS: a retrospective cohort study was conducted, including patients with a diagnosis of musculoskeletal tumor in the distal femur or proximal tibia, who underwent MKA between January 1, 2010, and December 31, 2021...
2024: Acta Ortopédica Mexicana
#40
REVIEW
Hua-Jay J Cherng, Alex Herrera
Diffuse large B-cell lymphoma (DLBCL) is a curable disease with variable outcomes due to underlying heterogeneous clinical and molecular features-features that are insufficiently characterized with our current tools. Due to these limitations, treatment largely remains a "one-size-fits-all" approach. Circulating tumor DNA (ctDNA) is a novel biomarker in cancers that is increasingly utilized for risk stratification and response assessment. ctDNA is readily detectable from the plasma of patients with DLBCL but has not yet been incorporated into clinical care to guide treatment...
April 24, 2024: Current Treatment Options in Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
